Related Experiment Video
Updated: May 17, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
[CMV and kidney transplant: prophylaxis and therapy]
Dino Sgarabotto1, Serena Marinello
1Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova - Italy.
Abstract:
Cytomegalovirus (CMV) infection is still an important cause of morbidity and mortality in kidney transplant recipients. Valganciclovir allows prophylaxis and therapy in an outpatient setting in most cases. PV16000, Victor and Impact200 are the double-blind multicenter studies which have introduced valganciclovir in everyday clinical practice. CMV-specific immunoglobulins are being used much less than before, except in the presence of hypogammaglobulinemia. Evaluation of specific CMV immunity with ELISPOT is introducing a promising new test to help clinicians in the management of CMV infection.
Insights
Cytomegalovirus (CMV) infection remains a significant risk for kidney transplant patients. Valganciclovir is now standard for prophylaxis and treatment, with ELISPOT emerging as a key diagnostic tool.
Area of Science:
- Nephrology
- Infectious Diseases
- Transplantation Immunology
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Cytomegalovirus Disease
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
